Solutions Accelerated by IsoPlexis

  • Cell & Gene Therapy

Apply PSI™ to CAR T-cell product release in a way that correlates to in vivo activity1

Detect the potent functional immune cell subsets that drive response and accelerate translational research.

Download application highlight

Research Area

Development Stage



Identify pre-infusion correlates to in vivo activity of cell therapy and patient outcome

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell


IsoPlexis’ PSI is able to stratify responders and non-responders

polyfunctional cell


Polyfunctional strength was found to correlate with objective response to CAR-T cell therapy, where other pre-infusion metrics did not

follow our data

Follow Our Data

See the latest published data in Cell Therapy

PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.

The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1

Download application highlight
PSI Predicts Clinical Outcomes


Detect Critical Differences

PSI outperformed other pre-infusion metrics, including IFN-g co-culture cytokine intensity, ratio of CD4+ to CD8+ T cells, and various T cell phenotype frequencies.1

PSI was the only metric that statistically differentiated responding from non-responding patients. The correlation of PSI with clinical outcome indicates the metric’s potential as a biomarker for guiding personalized CAR-T cell treatments and predicting therapeutic efficacy.1

PSI vs. Other Pre-Infusion Metrics

Request a Seminar

Request a Seminar
Discover IsoLight